Amgen Expects Palifermin BLA To Clear FDA Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral mucositis agent is receiving a "fast track" review, and Amgen is understood to be awaiting word from FDA in the next few days.